MP14-08 A MULTICENTER ASSESSMENT OF SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC) WHO RECEIVED IMMUNE CHECKPOINT INHIBITOR THERAPY (ICI) WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN)

Authors :: Steven K. Clinton
Amir Mortazavi
Abdul Miah
Evan Gross
Edmund Folefac
Evan T. Hall
Katharine Collier
Kaylee Oliva
Paul Monk
Megan Hinkley
Yuanquan Yang
John F. Thompson
John C. Gore
Delaney Orcutt
Joel Kramer
Duncan Hussey
Mingjia Li
Sherry Mori-Vogt
George R. Schade
Scott S. Tykodi
Sarah P. Psutka
Anish B. Parikh
Elliot Trott
Ming Yin
Daniel W. Lin
Source :: Journal of Urology. 206
Publication Year :: 2021
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2021.
Abstract: INTRODUCTION AND OBJECTIVE:The role of CN in the treatment of mRCC has been questioned with the recent approval of novel systemic therapy (ST) agents and the results of the CARMENA trial. Our objec...

Subjects :: Oncology
medicine.medical_specialty
business.industry
Urology
Immune checkpoint inhibitors
urologic and male genital diseases
medicine.disease
Systemic therapy
Renal cell carcinoma
Internal medicine
medicine
In patient
Cytoreductive nephrectomy
business

Full Text Access

Tools